Mini-Oral
Dato-DXd
ESMO 2025 | October 17-21, 2025
Genitourinary Cancers
Datopotamab deruxtecan (Dato-DXd) + rilvegostomig in patients with locally advanced or metastatic urothelial cancer: Results from the phase 2 TROPION-PanTumor03 study
Sun Young Rha
Poster
Pipeline Compounds
ASCO GU 2026 | February 26 - 28, 2026
Genitourinary Cancers
Efficacy and safety of the DLL3 T-cell engager gocatamig in participants with neuroendocrine prostate cancer and other neuroendocrine neoplasms
Himisha Beltran
Poster
R-DXd
ASCO GU 2026 | February 26 - 28, 2026
Genitourinary Cancers
REJOICE-PanTumor01: A phase 2 signal-seeking study of raludotatug deruxtecan    (R-DXd) in patients with advanced or metastatic gynecologic or genitourinary tumors
Laurence Albiges
Poster
T-DXd
ASCO GU 2026 | February 26 - 28, 2026
Genitourinary Cancers
Trastuzumab deruxtecan in pretreated patients with HER2-expressing bladder cancer: Final results from the bladder cancer cohort in part 1 of DESTINY-PanTumor02
Kyung Hae Jung
Poster
Dato-DXd
ASCO GU 2026 | February 26 - 28, 2026
Genitourinary Cancers
TROPION-Urothelial03: A phase 2/3 study of datopotamab deruxtecan (Dato-DXd) + platinum chemotherapy vs gemcitabine +platinum chemotherapy in participants with locally advanced or metastatic urothelial carcinoma with progression on or afterenfortumab vedotin + pembrolizumab
Matthew D. Galsky